CompletedPhase 4

Adenosine vs. Diltiazem

Turkey (Türkiye)140 participantsStarted 2024-07-01

Plain-language summary

In this Emergency Department (ED)-based study, the investigators evaluated a standardized modified Valsalva maneuver (MVM) as first-line therapy and compared intravenous (IV) adenosine with IV diltiazem among patients with persistent atrioventricular nodal re-entrant tachycardia (AVNRT)-consistent supraventricular tachycardia (SVT) after MVM, focusing on successful conversion to sinus rhythm. The investigators also assessed drug-related adverse events and clinically relevant treatment-course measures.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Presentation to the emergency department with hemodynamically stable, regular narrow-complex SVT consistent with AVNRT * a regular narrow-complex tachycardia with QRS duration \<120 ms * no discernible P waves on the presenting rhythm strip or 12-lead ECG * a ventricular rate of 160-220 beats/min Exclusion Criteria: * Contraindications to adenosine or diltiazem (known hypersensitivity to adenosine or diltiazem, prior heart transplantation, or concomitant dipyridamole/carbamazepine therapy) * Clinical evidence of impaired cerebral perfusion (e.g., altered mental status) * Pegnancy * Hemodynamic instability or respiratory failure requiring emergency intubation and advanced life support

What they're measuring

Conversion to sinus rhythm on continuous cardiac monitor/ECG without rescue therapy

Timeframe: Within 20 minutes after initiation of the assigned study drug

Trial details

NCT IDNCT07456423

SponsorHaseki Training and Research Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-30

View on ClinicalTrials.gov More Supraventricular Tachycardia (SVT) trials